Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.69 |
| ▸ | HPGD | P15428 | 7/20 | 0.66 |
| ▸ | NPC1 | O15118 | 5/20 | 0.60 |
| ▸ | RAB9A | P51151 | 5/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4195522 | 0.95 | ALDH1A1 (0.62) | ALDH1A1HPGDNPC1RAB9ARXFP1 | |
| SCHEMBL4690924 | 0.94 | HPGD (0.61) | ALDH1A1HPGDNPC1RAB9ARXFP1 | |
| SCHEMBL25240846 | 0.90 | ALDH1A1 (0.54) | ALDH1A1HPGDNPC1RAB9ARXFP1 | |
| SCHEMBL5219444 | 0.86 | MEN1 (0.56) | ALDH1A1HPGDNPC1RAB9ATSHR | |
| SCHEMBL475775 | 0.86 | MEN1 (0.56) | ALDH1A1HPGDNPC1RAB9ATSHR | |
| SCHEMBL4196712 | 0.84 | PKM (0.67) | ALDH1A1HPGDNPC1RAB9ARXFP1 | |
| SCHEMBL8134923 | 0.84 | HPGD (0.50) | ALDH1A1HPGDNPC1RAB9ARXFP1 | |
| SCHEMBL8144130 | 0.83 | ATM (0.52) | ALDH1A1HPGDNPC1RAB9ARXFP1 | |
| SCHEMBL5218738 | 0.82 | KMT2A (0.53) | ALDH1A1HPGDNPC1RAB9ATSHR | |
| SCHEMBL12359037 | 0.82 | ALDH1A1 (0.75) | ALDH1A1HPGDNPC1RAB9ARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106061480-B | Therapeutic inhibitory compounds | 莱福斯希医药公司 | 2020-02-28 | — | — | CN | disclosed |
| EP-1390340-B1 | COPPER-CATALYZED FORMATION OF CARBON-HETEROATOM AND CARBON-CARBON BONDS | MASSACHUSETTS INST TECHNOLOGY (US) | 2017-03-01 | — | — | EP | disclosed |
| EP-1390340-B1 | COPPER-CATALYZED FORMATION OF CARBON-HETEROATOM AND CARBON-CARBON BONDS | MASSACHUSETTS INST TECHNOLOGY (US) | 2017-03-01 | — | — | EP | disclosed |
| EP-3089746-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | Lifesci Pharmaceuticals, Inc. (BB) | 2016-11-09 | — | — | EP | disclosed |
| WO-2015103317-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | LIFESCI PHARMACEUTICALS, INC. (BB) | 2015-07-09 | — | — | WO | disclosed |
| WO-2015103317-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | LIFESCI PHARMACEUTICALS, INC. (BB) | 2015-07-09 | — | — | WO | disclosed |
| US-9067955-B2 | Copper-catalyzed formation of carbon-heteroatom and carbon—carbon bonds | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067955-B2 | Copper-catalyzed formation of carbon-heteroatom and carbon—carbon bonds | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-06-30 | — | — | US | disclosed |
| US-9067955-B2 | Copper-catalyzed formation of carbon-heteroatom and carbon—carbon bonds | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-06-30 | — | — | US | disclosed |
| CN-1854128-B | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | MASSACHUSETTS INST TECHNOLOGY | 2012-05-16 | — | — | CN | disclosed |
| US-20050215794-A1 | Copper-catalyzed formation of carbon heteroatom and carbon-carbon bonds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-09-29 | — | — | US | disclosed |
| US-6867298-B2 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2005-03-15 | — | — | US | disclosed |
| CN-1518534-A | Copper-catalyzed carbon-heteroatom and carbon-carbon bond formation | 麻省理工学院 | 2004-08-04 | — | — | CN | disclosed |
| US-6759554-B2 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2004-07-06 | — | — | US | disclosed |
| EP-1390340-A1 | COPPER-CATALYZED FORMATION OF CARBON-HETEROATOM AND CARBON-CARBON BONDS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2004-02-25 | — | — | EP | disclosed |
| US-20040019216-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-01-29 | — | — | US | disclosed |
| US-20030065187-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-04-03 | — | — | US | disclosed |
| US-6509359-B1 | Use as a neuramninidase inhibitor in virus | BIOCRYST PHARMACEUTICALS, INC. | 2003-01-21 | — | — | US | disclosed |
| WO-2002085838-A1 | COPPER-CATALYZED FORMATION OF CARBON-HETEROATOM AND CARBON-CARBON BONDS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2002-10-31 | — | — | WO | disclosed |
| WO-1999014191-A1 | PYRROLIDIN-2-ONE COMPOUNDS AND THEIR USE AS NEURAMINIDASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 1999-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215794-A1 | Copper-catalyzed formation of carbon heteroatom and carbon-carbon bonds | CBR3, ADH5, IDH1 | ALDH1A1 30/4885HPGD 562/4885NPC1 4440/4885 |
| US-20030065187-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | ADH5, CBR3, ALDH3A1 | ALDH1A1 26/4885HPGD 613/4885NPC1 4536/4885 |
| US-20040019216-A1 | Copper-catalyzed formation of carbon-heteroatom and carbon-carbon bonds | ADH5, CBR3, ALDH3A1 | ALDH1A1 26/4885HPGD 613/4885NPC1 4536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.